Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 29;67:103345. doi: 10.1016/j.ebiom.2021.103345

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 5 — CD8⁺ cell accumulation into the tumor. (a) Multiplex immunohistochemical staining of the tumors 7 days after the therapy. Top: cytokeratin staining to mark tumor tissue. Middle: lymphocyte marker staining; CD8 (magenta), CD4 (cyan) and Foxp3 (orange). The inset in the picture of CD25-PIT shows examples of CD8⁺ cell (gray filled arrowhead), CD4⁺Foxp3⁻ cell (white filled arrowhead) and CD4⁺Foxp3⁺ cell (open arrowhead). bottom: merged image. Scale bar, 100 μm. (b) intratumoral CD8⁺ cell density was significantly higher in the CD25-PIT group and the combined PIT group than the control group (n = 5; one-way ANOVA followed with Tukey's test; *, p < 0.05, **, p < 0.01). (c) intratumoral CD8⁺/CD4⁺Foxp3⁺ (Treg) ratio was also increased in these two groups compared with the control group (n = 5; one-way ANOVA followed with Tukey's test; *, p < 0.01; **, p < 0.05). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)